Monthly Archives: July 2012
This open-label, unblinded study included 257 patients in 53 US clinics with a diagnosis of CFS and FM. All subjects were given D-ribose (as Corvalen™ from Bioenergy), a naturally occurring pentose carbohydrate, 5 g t.i.d. for three weeks.
In the 203 patients who completed the trial, D-ribose treatment led to both statistically and clinically highly important average improvements in all categories:
- 61.3-percent increase in energy
- 37-percent increase in overall well being
- 29.3-percnet improvement in sleep
- 30-percent improvement in mental clarity
- 15.6-percent decrease in pain
Improvement began in the first week of treatment, and continued to increase at the end of the three weeks of treatment. The D-ribose was well tolerated.
These findings confirmed results of an earlier pilot study published in the Journal of Alternative and Complementary Medicine, involving 36 patients from a single medical centre, who took D-ribose for an average of 25 days. Approximately 66 percent of patients experienced significant improvement while on D-ribose, with an average increase in energy of 45 percent and an average improvement in overall well-being of 30 percent.
“Our hypothesis all along has been that giving D-ribose to people with chronic fatigue syndrome and fibromyalgia will jump-start their mitochondrial energy furnaces,” said Dr Teitelbaum. “We’re pleased that the larger multicentre trial corroborated our earlier study, showing the same benefits for fibromyalgia and chronic fatigue syndrome patients from multiple locations.”
I’m kinda feeling like a boat with no rudder, like I’m running but with nothing to run towards.
I had a wonderful goal – to establish a charity that would help FM sufferers who needed help, financially and emotionally. The initial aim was to start in Victoria and then move on to the remainder of Australia. I couldn’t even get 50 Victorian sufferers who were willing to give me their names so I could show that we needed this kind of help.
And then, of course, my plans were (essentially) shot down in flames by Arthritis Victoria – but, then again, who can blame them? If Victorian sufferers don’t think we deserve some help, why should other Victorians?
But, it leaves me rudderless.
I shall continue to try to raise awareness, and use all funds collected from my shops and donation page (hmm…need not worry about that one as no-one has donated a cent) towards making posters, postcards and brochures, etc and distributing them in any way I can but, I no longer have a specific goal – which makes me sad and kinda makes it difficult to muster the desire to write about stuff…
University of Utah Recruiting Fibromyalgia & FM/CFS Patients for Pregabalin Biomarker Study
The Department of Anesthesiology at the University of Utah, Salt Lake City, announced July 10 that it is seeking participants for a study to investigate Lyrica’s “effects on blood biomarkers” in patients with fibromyalgia or FM & chronic fatigue syndrome (ME/CFS).
Lyrica (pregabalin) is a prescription drug marketed by Pfizer that gained FDA approval in 2007* for treatment of fibromyalgia.
According to the July 10 blood biomarkers study announcement:
- Researchers hope to learn more about why Lyrica is effective for some patients and not for others.
- Volunteers with fibromyalgia (FMS) or chronic fatigue syndrome and FMS who are NOT currently using Lyrica are needed to participate in this IRB-approved trial.
- Eligible volunteers will receive Lyrica for five weeks and a placebo for five weeks, and will be compensated for their time.
- For more information, contact Andrea White (email@example.com)
* As Pfizer’s Lyrica patents begin expiring, in October 2013, the $3.4 billion annual Lyrica market will be opening to ‘generic’ (generally lower price – YIPPEE!) versions of the drug, and as of July 5, the FDA approved marketing of a generic pregabalin product by Lupin Pharmaceuticals.